197 related articles for article (PubMed ID: 27642100)
1. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.
Zhou YY; Zhu GQ; Liu T; Zheng JN; Cheng Z; Zou TT; Braddock M; Fu SW; Zheng MH
Sci Rep; 2016 Sep; 6():33743. PubMed ID: 27642100
[TBL] [Abstract][Full Text] [Related]
2. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.
Bosetti C; Franchi M; Nicotra F; Asciutto R; Merlino L; La Vecchia C; Corrao G
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):771-8. PubMed ID: 26013675
[TBL] [Abstract][Full Text] [Related]
3. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Zhou YY; Zhu GQ; Wang Y; Zheng JN; Ruan LY; Cheng Z; Hu B; Fu SW; Zheng MH
Oncotarget; 2016 Apr; 7(16):21753-62. PubMed ID: 26943041
[TBL] [Abstract][Full Text] [Related]
5. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.
Kawaguchi T; Taniguchi E; Morita Y; Shirachi M; Tateishi I; Nagata E; Sata M
Liver Int; 2010 Mar; 30(3):479-86. PubMed ID: 20040053
[TBL] [Abstract][Full Text] [Related]
6. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
7. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
8. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
9. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
10. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis.
Li J; Hernanda PY; Bramer WM; Peppelenbosch MP; van Luijk J; Pan Q
PLoS One; 2015; 10(6):e0127967. PubMed ID: 26030161
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials.
Jiang YF; Chen XY; Ding T; Wang XF; Zhu ZN; Su SW
J Clin Endocrinol Metab; 2015 May; 100(5):2071-80. PubMed ID: 25803270
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
Wang P; Kang D; Cao W; Wang Y; Liu Z
Diabetes Metab Res Rev; 2012 Feb; 28(2):109-22. PubMed ID: 21898753
[TBL] [Abstract][Full Text] [Related]
15. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
16. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.
Zhang ZJ; Zheng ZJ; Shi R; Su Q; Jiang Q; Kip KE
J Clin Endocrinol Metab; 2012 Jul; 97(7):2347-53. PubMed ID: 22523334
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
20. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]